Notably, comparisons between free OVA-anti-CTLA4 and (OVAinMOF)@(anit-CTLA4inMOF; Fig. 4), or between free OVA and OVAinMOF (Supplementary Fig. 30) show that only MOF has no significant improvement in progression-free survival, overall survival or tumour volume. Here, CTLA4 is linked to neoplasm.